Date: 2012-12-19
Type of information: Fundraising
Company: NeRRe Therapeutics (UK)
Investors: Novo A/S (Denmark)
Advent Venture Partners (UK)
GSK (UK)
Amount: £11.5 million (€14.1 million)
Funding type: series A financing round
Planned used: The funds will be used to support the progression of a portfolio of neurokinin receptor antagonists into clinical studies in diseases for which there is substantial unmet medical need.
Others: * On 19 December 2012, NeRRe Therapeutics Ltd is launched to develop a portfolio of clinical and pre-clinical neurokinin receptor antagonists divested from GSK. The Company will be based at the state-of-the-art Stevenage Bioscience Catalyst, the UK\'s first open innovation bioscience campus.
NeRRe Therapeutics has raised £11.5 million in Series A financing to support the progression of these molecules into clinical studies. The initial focus of the funding is on the most advanced neurokinin-1 receptor antagonist in this pipeline which is being repositioned for a new indication.
The Company founders, Dr Emiliangelo Ratti and Dr Mike Trower, are both former senior leaders of neurosciences drug discovery at GSK. Dr Ratti will become Chief Executive Officer of NeRRe and Dr Trower will take the role of Chief Scientific Officer. Dr Martin Edwards (Novo Ventures) and Dr Raj Parekh (AVP) will each join NeRRe’s Board.
Therapeutic area:
